Prima BioMed replaces director
Prima BioMed (ASX:PRR) has added former investment banker Pete Meyers to its board as a non-executive director.
Meyers is currently CFO of TetraLogic Pharmaceuticals, where he led the execution of its IPO in December.
Before joining TetraLogic, Meyers was an investment banker. Notable roles in the industry include co-head of global healthcare investment banking at Deutsche Bank in New York. He also held various roles at Dillon, Read & Co and Credit Suisse First Boston.
“I believe Pete’s depth of experience in the US capital markets, his network in the biotech community and his expertise advising healthcare companies will serve Prima well,” Prima Chairperson Lucy Turnbull said.
Meyers will be replacing Dr Richard Hammel, who is stepping down from the board after serving since January 2005.
Prima BioMed (ASX:PRR) shares were trading 4.08% higher at $0.051 as of around 2 pm on Tuesday.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
